Sonidegib: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Sonidegib. Educational only — not medical advice.

Labeled uses

ODOMZO (sonidegib) is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.

Source: FDA labeling via NIH DailyMed (set 028312dc…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.

Ratings summarize government-reported measures — they don't capture your personal needs. Visit the facility, ask about staffing and services, and use CMS checklists. This profile is informational only and is not a recommendation.